List of Rigel Pharmaceuticals patents

Patents where

Current Assignee

Name

Rigel Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 8637038 Methods for inhibiting allograft rejection	Patent 8637038 was granted and assigned to Rigel Pharmaceuticals on January, 2014 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	8637038	January 28, 2014
‌ US Patent 7557210 2,4-pyrimidinediamine compounds and their uses	Patent 7557210 was granted and assigned to Rigel Pharmaceuticals on July, 2009 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7557210	July 7, 2009
‌ US Patent 7488805 Apoptosis proteins	Patent 7488805 was granted and assigned to Rigel Pharmaceuticals on February, 2009 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7488805	February 10, 2009
‌ US Patent 7223850 Apoptosis proteins	Patent 7223850 was granted and assigned to Rigel Pharmaceuticals on May, 2007 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7223850	May 29, 2007
‌ US Patent 7300780 Germinal center kinase proteins, compositions, and methods of use	Patent 7300780 was granted and assigned to Rigel Pharmaceuticals on November, 2007 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7300780	November 27, 2007
‌ US Patent 10975064 RIP1 inhibitory compounds and methods for making and using the same	Patent 10975064 was granted and assigned to Rigel Pharmaceuticals on April, 2021 by the United States Patent and Trademark Office.	Rigel Pharmaceuticals	Rigel Pharmaceuticals	United States Patent and Trademark Office	10975064	April 13, 2021
‌ US Patent 7589200 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds	Patent 7589200 was granted and assigned to Rigel Pharmaceuticals on September, 2009 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7589200	September 15, 2009
‌ US Patent 7915293 Ubiquitin ligase inhibitors	Patent 7915293 was granted and assigned to Rigel Pharmaceuticals on March, 2011 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7915293	March 29, 2011
‌ US Patent 7034145 Directionally cloned random cDNA expression vector libraries, compositions and methods of use	Patent 7034145 was granted and assigned to Rigel Pharmaceuticals on April, 2006 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7034145	April 25, 2006
‌ US Patent 10259826 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds	Patent 10259826 was granted and assigned to Rigel Pharmaceuticals on April, 2019 by the United States Patent and Trademark Office.	Rigel Pharmaceuticals	Rigel Pharmaceuticals	United States Patent and Trademark Office	10259826	April 16, 2019
‌ US Patent 7420045 IAPs associated cell cycle proteins, compositions and methods of use	Patent 7420045 was granted and assigned to Rigel Pharmaceuticals on September, 2008 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7420045	September 2, 2008
‌ US Patent 7122630 SYK-UBP polypeptides and methods of making and isolating same	Patent 7122630 was granted and assigned to Rigel Pharmaceuticals on October, 2006 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7122630	October 17, 2006
‌ US Patent 7423118 IAPS associated cell cycle proteins, compositions and methods of use	Patent 7423118 was granted and assigned to Rigel Pharmaceuticals on September, 2008 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7423118	September 9, 2008
‌ US Patent 7122542 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds	Patent 7122542 was granted and assigned to Rigel Pharmaceuticals on October, 2006 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7122542	October 17, 2006
‌ US Patent 7132234 Methods and compositions for the identification of anti-poxvirus agents	Patent 7132234 was granted and assigned to Rigel Pharmaceuticals on November, 2006 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7132234	November 7, 2006
‌ US Patent 7485414 Modulators of angiogenesis	Patent 7485414 was granted and assigned to Rigel Pharmaceuticals on February, 2009 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7485414	February 3, 2009
‌ US Patent 7517886 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds	Patent 7517886 was granted and assigned to Rigel Pharmaceuticals on April, 2009 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7517886	April 14, 2009
‌ US Patent 7560466 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds	Patent 7560466 was granted and assigned to Rigel Pharmaceuticals on July, 2009 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7560466	July 14, 2009
‌ US Patent 7122332 Modulators of leukocyte activation, compositions and methods of use	Patent 7122332 was granted and assigned to Rigel Pharmaceuticals on October, 2006 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7122332	October 17, 2006
‌ US Patent 7358040 MRE 11: modulation of cellular proliferation	Patent 7358040 was granted and assigned to Rigel Pharmaceuticals on April, 2008 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7358040	April 15, 2008
‌ US Patent 9751893 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds	Patent 9751893 was granted and assigned to Rigel Pharmaceuticals on September, 2017 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	9751893	September 5, 2017
‌ US Patent 7449458 Prodrugs of 2,4-pyrimidinediamine compounds and their uses	Patent 7449458 was granted and assigned to Rigel Pharmaceuticals on November, 2008 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7449458	November 11, 2008
‌ US Patent 7384761 Methods of identifying an agent capable of interfering with Rad9 dephosphorylation	Patent 7384761 was granted and assigned to Rigel Pharmaceuticals on June, 2008 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7384761	June 10, 2008
‌ US Patent 7566765 Heterocyclic compounds containing a nine-membered carbon-nitrogen ring	Patent 7566765 was granted and assigned to Rigel Pharmaceuticals on July, 2009 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7566765	July 28, 2009
‌ US Patent 7118854 PAK2: modulators of lymphocyte activation	Patent 7118854 was granted and assigned to Rigel Pharmaceuticals on October, 2006 by the United States Patent and Trademark Office.		Rigel Pharmaceuticals	United States Patent and Trademark Office	7118854	October 10, 2006

...

Results per page:

426 results

0 selected

426 results

0 selected